Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 42 articles: HTML format

Single Articles

October 2025
1. ANESTOPOULOS I, Paraskevaidis I, Kyriakou S, Trafalis DT, et al
   Isothiocyanates Enhance the Anti-melanoma Effect of Entinostat Through Modulation of Apoptosis and HDACs' Expression Patterns in an In Vitro Model of Human Malignant Melanoma.
   Anticancer Res. 2025;45:4151-4167.
   PubMed     Abstract available
   
   
   September 2025
2. BRUNNER AS, Haddad S, Weise JJ, Wagenpfeil S, et al
   Malignant Melanoma: The Relationship Between Sunscreen Use and Cancer Risk - A Systematic Review and Meta-analysis.
   Anticancer Res. 2025;45:3595-3603.
   PubMed     Abstract available
   
   
   August 2025
3. AZUMI J, Takeda T, Shimada Y, Aso H, et al
   Combination of 3-(Trihydroxygermyl)propanoic Acid (THGP) and Lipopolysaccharide Promotes Macrophage Differentiation to M1, and Antitumor Activity.
   Anticancer Res. 2025;45:3425-3440.
   PubMed     Abstract available
   
   
   
4. YAMADA T, Iwasawa T, Shimizu Y, Kato K, et al
   Resveratrol Enhances Sulfasalazine-induced Ferroptosis by Promoting Iron Ion Accumulation and Lipid Peroxidation in Cancer Cells.
   Anticancer Res. 2025;45:3231-3244.
   PubMed     Abstract available
   
   
   June 2025
5. SUZUKI Y, Usuki S, Nishizawa M, Tanaka N, et al
   Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways.
   Anticancer Res. 2025;45:2265-2278.
   PubMed     Abstract available
   
   
   
6. YOON HS, Park YG, Cho DY, Kim JS, et al
   Antitumor Activity of Ex Vivo Expanded Tumor Antigen Priming Cytotoxic T Cells Against Malignant Melanoma.
   Anticancer Res. 2025;45:2339-2350.
   PubMed     Abstract available
   
   
   May 2025
7. YOSHIKAWA N, Ikushima C, Tanaka N, Iwata E, et al
   Role of Platelet Interactions in Promoting Melanoma Malignancy With Insights into Proliferation, Cyclin D1 Expression, and Migration.
   Anticancer Res. 2025;45:1927-1934.
   PubMed     Abstract available
   
   
   
8. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
   Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
   Anticancer Res. 2025;45:1807-1812.
   PubMed     Abstract available
   
   
   April 2025
9. YAMASHITA SN, Tanaka Y, Islam S, Kitagawa T, et al
   Increased Expression of DDX39 in Uveal Melanoma Is Associated With Patient Prognosis.
   Anticancer Res. 2025;45:1661-1666.
   PubMed     Abstract available
   
   
   March 2025
10. ZUPA A, Vita G, Omer LC, Calice G, et al
    NRAS(Q61K/R/L) Mutant Allele Frequency in Melanoma and its Correlation With Clinicopathological Characteristics.
    Anticancer Res. 2025;45:1015-1024.
    PubMed     Abstract available
    
    
    
11. POPP R, Savaliya BP, Raikot SR, Ahmed SH, et al
    Impact of Surgical Refusal on Overall Survival in Patients With Melanoma: A Comprehensive Analysis.
    Anticancer Res. 2025;45:1063-1070.
    PubMed     Abstract available
    
    
    February 2025
12. GKIONIS IG, Tzardi M, Alegakis A, Datseri G, et al
    Cyclin E Expression and p16 Loss Are Strong Prognostic Biomarkers in Primary Invasive Cutaneous Melanoma.
    Anticancer Res. 2025;45:625-637.
    PubMed     Abstract available
    
    
    January 2025
13. HASHIGUCHI S, Tanaka T, Mano R, Kondo S, et al
    SLC7A11/xCT-mediated Cystine Uptake Regulates Intracellular Glutathione and Promotes Antioxidant Defense in Lymphatic Endothelial Cells.
    Anticancer Res. 2025;45:65-71.
    PubMed     Abstract available
    
    
    
14. HADDAD S, Weise JJ, Wagenpfeil S, Vogt T, et al
    Malignant Melanoma: Vitamin D Status as a Risk and Prognostic Factor - Meta-analyses and Systematic Review.
    Anticancer Res. 2025;45:27-37.
    PubMed     Abstract available
    
    
    December 2024
15. BASU D
    Therapeutic Strategies in Neurocutaneous Melanocytosis.
    Anticancer Res. 2024;44:5157-5167.
    PubMed     Abstract available
    
    
    
16. SIN J, Kiosea M, Kiosea N, Mahdavi K, et al
    Investigation of Effectiveness of Nowarta110 Against Murine Malignant Melanoma in an Implanted Animal Model.
    Anticancer Res. 2024;44:5219-5224.
    PubMed     Abstract available
    
    
    
17. KANAI M, Shinagawa A, Ota M, Virgona N, et al
    Resveratrol Can Differentiate Human Melanoma Stem-like Cells from Spheroids Treated With All-trans Retinoic Acid.
    Anticancer Res. 2024;44:5283-5292.
    PubMed     Abstract available
    
    
    
18. CHO Y, Kim HS
    Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.
    Anticancer Res. 2024;44:5515-5524.
    PubMed     Abstract available
    
    
    September 2024
19. FRACCAROLI A, Barnikel M, Scheubeck G, Buchstab O, et al
    Stealthy Invader: Clinically Inapparent But Rapidly Progressive Multifocal Metastatic Melanoma Unveiled as Root Cause of Liver Failure.
    Anticancer Res. 2024;44:4127-4132.
    PubMed     Abstract available
    
    
    
20. GAO YU, Wendt S, Krohn S, Alammar M, et al
    Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.
    Anticancer Res. 2024;44:3843-3848.
    PubMed     Abstract available
    
    
    
21. MA W, Li Z, Wen J, Yan S, et al
    The Expression and Prognostic Value of Multiple Glucose Transporters in Cutaneous Melanoma.
    Anticancer Res. 2024;44:3747-3756.
    PubMed     Abstract available
    
    
    August 2024
22. JU M, Minami K, Katsuki S, Takenaka W, et al
    Synergistic Effects of Melatonin on Radiosensitization in Carbon-ion Radiotherapy.
    Anticancer Res. 2024;44:3295-3306.
    PubMed     Abstract available
    
    
    
23. SURESHKUMAR H, Eathara A, Datta A, Alahmadi R, et al
    Association Between Uveal Melanoma and Allostatic Load.
    Anticancer Res. 2024;44:3375-3380.
    PubMed     Abstract available
    
    
    June 2024
24. WEN X, Han M, Hosoya M, Toshima R, et al
    Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.
    Anticancer Res. 2024;44:2349-2358.
    PubMed     Abstract available
    
    
    March 2024
25. FERNANDO PDSM, Zhen AX, Piao MJ, Herath HMUL, et al
    Naringenin Induces Cellular Apoptosis in Melanoma Cells via Intracellular ROS Generation.
    Anticancer Res. 2024;44:1079-1086.
    PubMed     Abstract available
    
    
    February 2024
26. POPP K, Popp R, Bansal S, Sharan S, et al
    Disparities in Time-to-treatment for Patients With Melanoma.
    Anticancer Res. 2024;44:631-637.
    PubMed     Abstract available
    
    
    
27. SCALIA G, Silven MP, Costanzo R, Porzio M, et al
    Intraventricular Cerebral Metastases: A Comprehensive Systematic Review.
    Anticancer Res. 2024;44:453-462.
    PubMed     Abstract available
    
    
    January 2024
28. CESAR MCM, Mortara RA, Souza VS, Alves VRG, et al
    Peptide L13S Derived from the BRN2 POU Domain Reduces Metastasis In Vivo and Inhibits Cell Migration and Invasion In Vitro.
    Anticancer Res. 2024;44:71-84.
    PubMed     Abstract available
    
    
    
29. WALZ SN, Martineau J, Scampa M, Madduri S, et al
    Incidence Trends of Melanoma of the Lower Limbs and Hips in the United States: A Surveillance, Epidemiology, and End Results Analysis 2000-2019.
    Anticancer Res. 2024;44:239-247.
    PubMed     Abstract available
    
    
    
30. KELEMEN G, Egyud Z, Dobi A, Varga L, et al
    Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma.
    Anticancer Res. 2024;44:205-212.
    PubMed     Abstract available
    
    
    October 2023
31. GLASER N, Petzold A, Wessely A, Kaufmann MD, et al
    Threshold Optimization for Tumor Markers S100b and MIA in Uveal Melanoma - A Single Center Analysis.
    Anticancer Res. 2023;43:4525-4532.
    PubMed     Abstract available
    
    
    
32. TASSAVOR M, Martin BJ, Glazer AM
    The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
    Anticancer Res. 2023;43:4511-4516.
    PubMed     Abstract available
    
    
    
33. DURZYNSKA M, Dos Santos FLC, Matuszczyk A, Derezinska-Wolek E, et al
    Prognostic Implications of PRAME Expression and Clinicopathological Factors in Sinonasal Mucosal Melanoma: A Single-center Cohort Study of 30 Cases.
    Anticancer Res. 2023;43:4551-4557.
    PubMed     Abstract available
    
    
    September 2023
34. WALZ SN, Martineau J, Scampa M, Madduri S, et al
    Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019.
    Anticancer Res. 2023;43:4105-4113.
    PubMed     Abstract available
    
    
    August 2023
35. KIM Y, Kim JE, Lee DY, Choi JU, et al
    T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
    Anticancer Res. 2023;43:3419-3427.
    PubMed     Abstract available
    
    
    June 2023
36. WANG CH, Wang LK, Wu CC, Chen ML, et al
    TIG1 Inhibits the mTOR Signaling Pathway in Malignant Melanoma Through the VAC14 Protein.
    Anticancer Res. 2023;43:2635-2643.
    PubMed     Abstract available
    
    
    
37. HIPPNER-KUNICKA M, Laszkiewicz A, Skrzymowska J, Biecek P, et al
    Overexpression of c-MYC Promoter Binding Protein-1 Enhances Proliferation and Glucose Metabolism of Melanoma Cells Lines.
    Anticancer Res. 2023;43:2527-2538.
    PubMed     Abstract available
    
    
    April 2023
38. FRIEDLANDER P, Morgan LR, Benes EN, Rodgers AH, et al
    Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
    Anticancer Res. 2023;43:1407-1413.
    PubMed     Abstract available
    
    
    
39. GRUJIC M, Nguyen T, Hechard T, Wang H, et al
    Phenotypic Switch and Growth of Melanoma Spheroids in the Presence of Mast Cells: Potential Impact of Nutrient-starvation Effects.
    Anticancer Res. 2023;43:1415-1426.
    PubMed     Abstract available
    
    
    
40. JARELL A, Fernandes N
    Letter to the Editor: RE: de Gruijl and Armstrong: Cutaneous Melanoma: Sheep in Wolves Clothing? Anticancer Res 42(10): 5021-5025, 2022.
    Anticancer Res. 2023;43:1873-1874.
    PubMed    
    
    
    
41. SASAKI K, Hirohashi Y, Murata K, Minowa T, et al
    SOX10 Inhibits T Cell Recognition by Inducing Expression of the Immune Checkpoint Molecule PD-L1 in A375 Melanoma Cells.
    Anticancer Res. 2023;43:1477-1484.
    PubMed     Abstract available
    
    
    March 2023
42. POOMMARAPAN K, Rummaneethorn P, Srisubat A, Suwanpidokkul N, et al
    Gene Profiling of Cannabis-sativa-mediated Apoptosis in Human Melanoma Cells.
    Anticancer Res. 2023;43:1221-1237.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.